TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nursing home clinicians say more residents are arriving on GLP-1 medications, now used for conditions beyond diabetes and weight loss. Operators are adjusting assessments and monitoring, while payment rules leave some residents and facilities exposed to substantial costs.
GLP-1 medications are appearing more often among nursing home residents, including people admitted already taking the drugs, according to clinicians and operators interviewed by Skilled Nursing News. The increase is expanding staff monitoring needs and exposing residents and facilities to uncertain medication costs, while a temporary Medicare coverage program remains in place and a more permanent option is delayed.
Lisa Chubb, chief nursing officer for New Jersey-based Venza Care, told Skilled Nursing News that about 30% to 40% of new admissions at the operator are taking GLP-1s. She said the share is higher at facilities with more short-stay residents. Chubb described use expanding beyond diabetes and weight loss to cardiovascular prevention and other chronic conditions, as well as metabolic and organ health. Those are reported clinical uses and goals; the source does not provide outcome data establishing their effects in nursing home residents.
At Venza, interdisciplinary teams discuss residents at risk nutritionally in weekly meetings, use customized electronic health record assessments to document medication review and education, and monitor weight. Registered dietitians are involved in care for residents taking these drugs, Chubb said. The measures reflect concern that weight loss may come with muscle weakness or frailty, making the balance between a resident’s preferences and potential complications a case-by-case issue.
Payment depends on the resident’s coverage and prescription. Jessie McGill of the American Association for Post-Acute Care Nursing (AAPACN) said Medicare Part D’s temporary bridge program covers certain GLP-1s prescribed for weight loss for eligible residents, with a $50 monthly fee in addition to Part D coverage. The program includes Wegovy, Zepbound and Foundeo, according to McGill. She said that charge can still be difficult for residents with limited means. For some residents receiving Medicare Part A in a nursing home, McGill said, the facility is responsible for the medication cost; a drug outside the bridge program may be a significant operating expense.
Medication Costs Meet Nursing Home Care
The reported increase matters because nursing homes must manage these medications within settings where residents may already have frailty, multiple chronic conditions, nutritional risk or limited functional ability. A treatment associated with weight loss in other settings may not have the same implications for every older adult. Clinicians need to track nutrition, weight and possible adverse effects while coordinating across nursing, dietary and other care teams.
Costs also affect more than the resident’s prescription budget. Jody O’Mara, chief nursing officer for Journey Skilled Nursing, said high-cost medications become a facility cost in some arrangements, including the pharmacy joint venture the operator was discussing for Georgia residents. O’Mara said she believes the benefits outweigh the expense, but that is her assessment, not a quantified finding in the report. The unresolved payment rules may influence how operators plan budgets and assess admissions involving these drugs.
Products Worth Considering
Levoit Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft²
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Levoit EverestAir-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Temporary Medicare Coverage Rules
According to AAPACN’s McGill, the Medicare Part D bridge program offers coverage for certain GLP-1 prescriptions for weight loss when the resident has not already been prescribed a GLP-1 for diabetes, which is covered under Part D. Eligibility also depends on program criteria, including BMI categories and related chronic conditions, she said. The source does not provide the full criteria or a resident-by-resident eligibility determination.
A more permanent coverage approach, called BALANCE, was delayed without a new implementation date. The bridge program was extended through 2027. McGill said nursing facilities can face costs for residents covered under Medicare Part A, and argued that Congress could consider expanding consolidated billing to include high-cost medicines such as GLP-1s. She noted that certain drugs, including chemotherapy and dialysis medications, are excluded from consolidated billing and can be billed to Medicare Part B directly.
“We see a lot of our new admissions coming in with GLP-1s.”
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Resident Outcomes
Key details remain unsettled. BALANCE has no announced start date, and the source does not specify whether further changes to the bridge program will follow its extension through 2027. The report also does not quantify how many residents qualify, how much facilities spend overall, or how costs vary across different Medicare and Medicaid arrangements.
Clinical outcomes among nursing home residents are also not established in the supplied reporting. The article describes clinicians’ expectations and concerns, but does not provide comparative evidence on benefits or harms for this population. Individual prescribing decisions, residents’ nutritional status, and how facilities respond to adverse effects will vary.
Operators Prepare for Continued Use
For now, nursing homes are adapting through medication reviews, staff education, nutrition assessments and closer weight monitoring, according to Chubb. O’Mara said GLP-1 use could affect facility assessments, decisions about which residents to admit and quality assurance and performance improvement programs. Those changes are operational plans and expectations, not evidence that all facilities have adopted the same approach.
The immediate policy marker is the bridge program’s extension through 2027. A permanent coverage date has not been announced. McGill said expanding consolidated billing to include high-cost medicines would require action by Congress. Until payment rules change or become clearer, residents, prescribers and nursing home operators will continue to weigh eligibility, out-of-pocket charges and facility responsibility alongside each resident’s clinical needs.
Key Questions
Why are more nursing home residents taking GLP-1 medications?
Clinicians report that use is extending beyond diabetes and weight loss to other chronic conditions and cardiovascular prevention. The report does not establish outcomes for these uses among nursing home residents.
Does Medicare cover GLP-1 drugs for weight loss in nursing homes?
A temporary Medicare Part D bridge program covers certain eligible weight-loss prescriptions, according to AAPACN’s Jessie McGill. The program includes Wegovy, Zepbound and Foundeo and adds a $50 monthly fee; eligibility rules apply.
Who may pay when a resident is taking a GLP-1?
Payment depends on coverage, the prescription and the resident’s stay. McGill said a facility may be responsible for medication costs for some residents on Medicare Part A, particularly when a drug is not covered through the bridge program.
What risks are nursing home clinicians monitoring?
Clinicians cited concerns including muscle weakness, frailty and nutritional risk. AAPACN’s Lauren Stenson also named nausea, vomiting, constipation and dehydration as possible adverse effects.
Source: skillednursingnews.com
